Novartis Seeks COVID-19 Antiviral Candidate Authorization

Novartis Seeks COVID-19 Antiviral Candidate Authorization

February 10, 2022 • 11:24 am CST

https://www.precisionvaccinations.com/2022/02/10/novartis-seeks-covid-19-antiviral-candidate-authorization

(Precision Vaccinations)

Switzerland-based Molecular Partners AG today announced its partner Novartis had requested Emergency Use Authorization from the U.S. FDA for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

Ensovibep is explicitly designed to inhibit target cell entry of the SARS-CoV-2 beta coronavirus.

This FDA submission is based on the totality of clinical and preclinical studies data, including the positive results of the Phase 2 portion of the EMPATHY study. This randomized, placebo-controlled study enrolled 407 symptomatic patients infected with SARS-CoV-2.

DARPins (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies designed to engage their targets for various effects specifically.

Ensovibep includes three covalently linked individual DARPin domains that bind to the spike protein of SARS-CoV-2.

With these domains incorporated into a single molecule, ensovibep is designed to block the receptor-binding domain of the SARS-CoV-2 spike protein, even in the presence of some mutations of the spike protein.

Several characteristics of DARPin therapeutics make them potentially suitable for COVID-19 treatment, including multi-specific binding, the rapid onset of action, and scalable bacterial production.

"We are pleased that the results from the EMPATHY trial demonstrate the positive therapeutic effect of ensovibep, with the potential to be an important new treatment option to combat the rapidly evolving SARS-CoV-2 pandemic," commented Vas Narasimhan, CEO of Novartis, in a press release issued on January 10, 2022.

"As COVID-19 continues to burden healthcare systems across the globe, a range of treatments will be needed, and Novartis is proud to continue our collaboration with Molecular Partners on this unique treatment for COVID-19 and contribute ensovibep to this suite of options." 

Molecular Partners and Novartis entered into a license agreement on January 18, 2022, under which Novartis in-licensed global rights to ensovibep.

Connecting the Dots:

Novartis Corporation is a U.S. subsidiary of Novartis AG and a member of the Pharmaceutical Research and Manufacturers of America.

Akin, Gump, Strauss, Hauer & Feld, LLP is the lobby firm for the Novartis Corporation and the Pharmaceutical Research and Manufacturers of America.

Vernon E. Jordan Jr. is a senior counsel for Akin, Gump, Strauss, Hauer & Feld, LLP and an honorary trustee at the Brookings Institution (think tank).

Foundation to Promote Open Society was a funder for the Brookings Institution (think tank) and the Carnegie Endowment for International Peace (think tank).

George Soros was the chairman for the Foundation to Promote Open Society.

James F. Collins is a senior associate at the Carnegie Endowment for International Peace (think tank) and was a senior advisor for Akin, Gump, Strauss, Hauer & Feld, LLP.

Ed Griffin’s interview with Norman Dodd in 1982

(The investigation into the Carnegie Endowment for International Peace uncovered the plans for “Population Control” by involving the United States in war)

http://www.illuminati-news.com/110106a.htm

Donald Kennedy was a trustee at the Carnegie Endowment for International Peace (think tank) and a commissioner for the U.S. Food and Drug Administration (FDA).

William W. George is a trustee at the Carnegie Endowment for International Peace (think tank) and was a director at Novartis AG.

Daniel Vasella is a trustee at the Carnegie Endowment for International Peace (think tank) and was the chairman for Novartis AG.

Carnegie Endowment for International Peace (think tank) was a funder for the Nuclear Threat Initiative (think tank).

Margaret A. Hamburg is a VP for the Nuclear Threat Initiative (think tank) and the commissioner for the U.S. Food and Drug Administration (FDA).

Jessica Tuchman Mathews is a director at the Nuclear Threat Initiative (think tank), the president of the Carnegie Endowment for International Peace (think tank), was an honorary trustee at the Brookings Institution (think tank).

Foundation to Promote Open Society was a funder for the Carnegie Endowment for International Peace (think tank) and the Brookings Institution (think tank).

George Soros was the chairman for the Foundation to Promote Open Society.

Mark B. McClellan was a senior fellow at the Brookings Institution (think tank) and a commissioner for the U.S. Food and Drug Administration (FDA).

Ann M. Fudge is a trustee at the Brookings Institution (think tank) and a director at Novartis AG.

Klaus Kleinfeld is a trustee at the Brookings Institution (think tank) and a trustee at the Conference Board (think tank). 

Marjorie M.T. Yang was a trustee at the Conference Board (think tank) and is a director at Novartis AG.

Novartis Corporation is a U.S. subsidiary of Novartis AG and a member of the Pharmaceutical Research and Manufacturers of America.

Resources: Past Research

Neurologist Claims There Is No Such Thing as ADHD (Past Research on Novartis AG)

THURSDAY, MARCH 13, 2014

https://thesteadydrip.blogspot.com/2014/03/neurologist-claims-there-is-no-such.html